Journal of the National Cancer Institute Advance Access originally published online on July 10, 2007
JNCI Journal of the National Cancer Institute 2007 99(14):1063; doi:10.1093/jnci/djm063
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© The Author 2007. Published by Oxford University Press.
EDITORIALS |
The Origin of Kaposi Sarcoma
Correspondence to: Parkash S. Gill, MD, Department of Medicine and Pathology, Norris Cancer Hospital and Research Institute, University of Southern California, 1441 Eastlake Ave, Rm 3458, Los Angeles, CA 90033 (e-mail: parkashg@hsc.usc.edu).
| The first 10% of the full text of this article appears below. |
Kaposi sarcoma (KS) is distinct from other cancers in multiple ways. The most remarkable difference is that it first manifiests itself as many distinct tumor lesions at discrete locations. KS is associated with HHV8 infection, whether it develops in the setting of HIV infection and concomitant use of immune-suppressive agents or in older men of Mediterranean descent. Another notable feature of KS is its regression upon withdrawal of immune suppressive agents (or
Funding
Related Articles in JNCI
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2007 99: 1086-1094.
J Natl Cancer Inst 2007 99: 1057.
J Natl Cancer Inst 2007 99: 1057.